April 1, 2019
The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing new adverse reaction risks for a slew of drugs including SGLT2 inhibitors and Ono Pharmaceutical’s Opdivo (nivolumab) - a move that is likely to result in label changes - according to...read more